Compare RMCO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | DYAI |
|---|---|---|
| Founded | 2021 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 32.5M |
| IPO Year | 2021 | 2003 |
| Metric | RMCO | DYAI |
|---|---|---|
| Price | $2.83 | $0.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 14.8K | ★ 169.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,949,916.00 | $3,090,345.00 |
| Revenue This Year | $209.10 | $122.79 |
| Revenue Next Year | $133.33 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | N/A |
| 52 Week Low | $1.71 | $0.65 |
| 52 Week High | $5.00 | $1.60 |
| Indicator | RMCO | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 32.30 |
| Support Level | $2.72 | N/A |
| Resistance Level | $3.04 | $0.91 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 61.62 | 1.92 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.